Received Oct 16, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 1 | — | — |
No additional AE; it has been over 5 months since the patient received her first dose of the GARDASIL 9 vaccine and has not yet received her second dose of the vaccine.; This spontaneous report was received from a Registered Nurse and refers to a 31-year-old female patient. The patient's concurrent conditions, medical history, previous drug reactions, drug allergies and concomitant therapies were not reported. In March 2025, the patient was vaccinated with the first dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL®9) (route of administration, site of administration, lot #, and expiration date were not provided) as prophylaxis. In approximately October 2025 (Reported as over 5 months), the patient had not yet received her second dose of the vaccine (Inappropriate schedule of product administration). No additional adverse event reported.